TempraMed Technologies Ltd.

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed’s full product portfolio  Vancouver, BC – February 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator...

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channels Highlights -          Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature-          Designed for medications...

Validation is expected to accelerate TempraMed’s path to payor reimbursement for product portfolio Highlights -          ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility-          Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment-          Supports TempraMed’s planned...

Vancouver, BC – January 12, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each,...

Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activities Vancouver, BC - January 7, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial...

Vancouver, BC – January 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead...

Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected “VIVI Cap Smart” device Vancouver, BC – December 31, 2025 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed,...

Integrated smart technology builds on TempraMed’s proven VIVI platform, providing robust Temperature control with  medication management for individuals using life-saving medication Highlights:  Expands TempraMed’s product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost  every insulin and GLP-1 pens to...

New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for products Highlights:  -          Manufacturing site in Florida expands TempraMed’s U.S. production footprint-          Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers-          Shortens delivery...

Highlights -          Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture-          Expands the Company’s ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics-          Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia’s premium...

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership. Vancouver, BC – December 10, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr....

Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI...